Melatonin as a chronobiotic/cytoprotective agent in bone. Doses involved

Area of Science:

• Chronobiology
• Bone Biology
• Gerontology

Background:

• Melatonin levels decline with age, impacting postmenopausal and senescence pathology.
• Bone is a target site for melatonin's chronobiotic effects via MT1 and MT2 receptors.
• Melatonin may act as a cytoprotective autacoid on bone marrow precursors.

Purpose of the Study:

• To investigate the role of melatonin in bone health, particularly in aging and postmenopausal individuals.
• To explore melatonin's effects on bone cells, including osteoblasts and osteoclasts.
• To evaluate the potential of melatonin, including higher doses, in preventing bone loss.

Main Methods:

• Review of existing literature on melatonin's effects on bone.
• Analysis of melatonin's influence on bone cell precursors and matrix proteins like procollagen type I c-peptide.
• Examination of melatonin's impact on osteoprotegerin and osteoclast activity.
• Consideration of melatonin's free radical scavenging properties in relation to bone resorption.

Main Results:

• Melatonin exposure augments bone matrix proteins and osteoprotegerin, an inhibitor of osteoclast differentiation.
• Melatonin impairs osteoclast activity and bone resorption through its free radical scavenger properties.
• Current clinical studies often use lower melatonin doses than those suggested by allometric derivations from animal studies.

Conclusions:

• Melatonin demonstrates potential as a cytoprotective agent for bone cells and may inhibit bone resorption.
• Higher doses of melatonin, not commonly used clinically, warrant further investigation for enhanced therapeutic efficacy in preventing bone loss.
• The absence of toxicity in high-dose studies suggests potential for exploring higher melatonin dosages in bone health interventions.